Search Results

Cofactor Genomics, the company bridging the precision medicine gap, today announced successful validation of the OncoPrism immunotherapy predictive diagnostic assay, enabling physicians to use the test to help guide treatment decisions for patients with metastatic or recurrent squamous cell carcinoma of the head and neck (HNSCC).

Stanford University and Cofactor Genomics, the company bridging the precision medicine gap, announced that Stanford will join Cofactor’s PREDAPT clinical trial evaluating use of the company’s OncoPrism™ predictive diagnostic assay across 11 cancers.

Culmination Bio today announced a partnership to leverage samples and data from one of the largest biobanks in the country to fuel the development of Cofactor Genomic’s OncoPrism™ test in 11 cancers.

AI-Powered Genomic Mapping Could Revolutionize Treatment of Rare Genetic Diseases

Cofactor Genomics, the diagnostics company bridging the precision medicine gap, today announced commencement of a study of its OncoPrism™ assay in non-small cell lung cancer (NSCLC), the second indication being studied in the company’s national PREDAPT study that will ultimately encompass 11 cancers.

Cofactor Genomics, a Predictive Immune Modeling company, today presented initial results from the PREDAPT